A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
authorize a program to support the adoption of, and 
improve the development of, innovative approaches to 
pharmaceutical product design and manufacturing, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Drug Manufacturing 
4
Innovation Act of 2022’’. 
5
02:38 Mar 10, 2022
H6988
2 
•HR 6988 IH
SEC. 2. EMERGING TECHNOLOGY PROGRAM. 
1
Chapter V of the Federal Food, Drug, and Cosmetic 
2
Act (21 U.S.C. 201 et seq.) is amended by inserting after 
3
section 566 of such Act (21 U.S.C. 360bbb–5) the fol-
4
lowing: 
5
‘‘SEC. 566A. EMERGING TECHNOLOGY PROGRAM. 
6
‘‘(a) PROGRAM ESTABLISHMENT.— 
7
‘‘(1) IN GENERAL.—The Secretary shall estab-
8
lish a program to support the adoption of, and im-
9
prove the development of, innovative approaches to 
10
pharmaceutical product design and manufacturing. 
11
‘‘(2) ACTIONS.—In carrying out the program 
12
under paragraph (1), the Secretary may— 
13
‘‘(A) facilitate and increase communication 
14
between public and private entities, consortia, 
15
and individuals with respect to innovative phar-
16
maceutical product design and manufacturing; 
17
‘‘(B) solicit information regarding, and 
18
conduct or support research on, innovative ap-
19
proaches to pharmaceutical product design and 
20
manufacturing; 
21
‘‘(C) convene meetings with representatives 
22
of industry, academia, other Federal agencies, 
23
international agencies, and other interested per-
24
sons, as appropriate; 
25
02:38 Mar 10, 2022
H6988
3 
•HR 6988 IH
‘‘(D) convene working groups to support 
1
pharmaceutical product design and manufac-
2
turing research and development; 
3
‘‘(E) support education and training for 
4
regulatory staff and scientists related to innova-
5
tive approaches to pharmaceutical product de-
6
sign and manufacturing; 
7
‘‘(F) conduct research and testing to de-
8
velop or validate innovative approaches to phar-
9
maceutical product design and manufacturing; 
10
‘‘(G) advance regulatory science related to 
11
the development and review of innovative ap-
12
proaches to pharmaceutical product design and 
13
manufacturing; 
14
‘‘(H) convene working groups to support 
15
the harmonization of international regulatory 
16
requirements related to innovative approaches 
17
to pharmaceutical product design and manufac-
18
turing; and 
19
‘‘(I) award grants or contracts to carry out 
20
or support the program under paragraph (1). 
21
‘‘(3) GRANTS
AND
CONTRACTS.—To seek a 
22
grant or contract under this section, an entity shall 
23
submit an application— 
24
02:38 Mar 10, 2022
H6988
4 
•HR 6988 IH
‘‘(A) in such form and manner as the Sec-
1
retary may require; and 
2
‘‘(B) containing such information as the 
3
Secretary may require, including a description 
4
of— 
5
‘‘(i) how the entity will conduct the 
6
activities to be supported through the 
7
grant or contract; and 
8
‘‘(ii) how such activities will further 
9
research and development related to, or 
10
adoption of, innovative approaches to phar-
11
maceutical product design and manufac-
12
turing. 
13
‘‘(b) GUIDANCE.—The Secretary shall— 
14
‘‘(1) issue or update guidance to help facilitate 
15
the adoption of, and advance the development of, in-
16
novative approaches to pharmaceutical product de-
17
sign and manufacturing; and 
18
‘‘(2) include in such guidance descriptions of— 
19
‘‘(A) any regulatory requirements related 
20
to the development or review of technologies re-
21
lated to innovative approaches to pharma-
22
ceutical product design and manufacturing, in-
23
cluding regulatory requirements necessary for 
24
02:38 Mar 10, 2022
H6988
5 
•HR 6988 IH
updates and improvements to such technologies 
1
after product approval; and 
2
‘‘(B) data required to demonstrate the 
3
identity, safety, purity, and potency of drugs 
4
manufactured using such technologies. 
5
‘‘(c) REPORT TO CONGRESS.—Not later than 4 years 
6
after the date of enactment of this section, the Secretary 
7
shall submit to the Committee on Energy and Commerce 
8
of the House of Representatives and the Committee on 
9
Health, Education, Labor, and Pensions of the Senate a 
10
report containing— 
11
‘‘(1) an annual accounting of the allocation of 
12
funds made available to carry out this section; 
13
‘‘(2) the number of full-time equivalent staff 
14
dedicated to the program under subsection (a)(1); 
15
‘‘(3) the number of meetings held by the Food 
16
and Drug Administration, including meetings con-
17
vened as part of a working group described in sub-
18
paragraph (D) or (H) of paragraph (2) of subsection 
19
(a), and the topics of each such meeting; and 
20
‘‘(4) the number of products approved or li-
21
censed, after the date of enactment of this section, 
22
using an innovative approach to pharmaceutical 
23
product design and manufacturing. 
24
02:38 Mar 10, 2022
H6988
6 
•HR 6988 IH
‘‘(d) AUTHORIZATION
OF
APPROPRIATIONS.—To 
1
carry out this section, there is authorized to be appro-
2
priated $20,000,000 for each fiscal year 2023 through 
3
2027.’’. 
4
Æ 
02:38 Mar 10, 2022
H6988
